Biomedical Engineering Reference
In-Depth Information
65. Iscan, Y. Y.; Hekimoglu, S.; Kas, S.; Hinca, A. A.
Formulation and Characterization of Solid
Lipid Nanoparticles for Skin Delivery, Conference Lipid and Surfactant Dispersed Systems
;
Proceedings Topic: Moscow, Russia, 1999, 163-166.
66. Schwarz, C.; Freitas, C.; Mehnert, W.; MuÈller, R. H. Sterilisation and Physical Stability
of Drug-Free and Etomidate-Loaded Solid Lipid Nano-particles.
Proc. Int. Symp. Control.
Release Bioact. Mater.
1995,
22,
766-767.
67. Muller, R. H.; Mader, K.; Gohla, S. Solid Lipid Nanoparticles (SLN) for Controlled Drug
Delivery ± A Review of the State of the Art.
Eur. J. Pharm. Biopharm.
2000,
50,
161-177.
68. Morel, S.; Terreno, E.; Ugazio, E.; Aime, S.; Gasco, M. R. NMR Relaxometric Investigations
of Solid Lipid Nanoparticles (SLN) Containing Gadolinium (III) Complexes.
Eur. J. Pharm.
Biopharm.
1998,
45,
157-163.
69. Gasco, M. R. Solid Lipid Nanospheres from Warm Micro-emulsions.
Pharm. Technol. Eur.
1997,
9,
52-58.
70. Boltri, L.; Canal, T.; Esposito, P. A.; Carli, F. Lipid Nanoparticles: Evaluation of Some Critical
Formulation Parameters.
Proc. Int. Symp. Control Release Bioact. Mater.
1993,
20,
346-347.
71. Mueller, R. H.; Schwarz, C.; Mehnert, W.; Lucks, J. S. Production of Solid Lipid Nanopar-
ticles (SLN) for Controlled Drug Delivery.
Proc. Int. Symp. Control Release Bioact. Mater.
1993,
20,
480-481.
72. Nobs, L.; Buchegger, F.; Gurny, R.; Allemann, E. Current Methods for Attaching Targeting
Ligands to Liposomes and Nanoparticles.
J. Pharm. Sci.
2004,
93,
1980-1992.
73. McCarthy, J. R.; Kelly, K. A.; Sun, E. Y.; Weissleder, R. Targeted Delivery of Multifunctional
Magnetic Nanoparticles.
Nanomedicine
2007,
2,
153-167.
74. Dagar, S.; Sekosan, M.; Lee, B. S.; Rubinstein, I.; Onyuksel, H. VIP Receptors as Molecular
Targets of Breast Cancer: Implications for Targeted Imaging and Drug Delivery.
J. Contr.
Release
2001,
74,
129-134.
75. Sethi, V.; Onyuksel, H.; Rubinstein, I. A novel therapy for rheumatoid arthritis using a-helix
VIP, FASEB 2003 conference proceedings.
FASEB
2003,
660.
76. Lee, J.; Cho, E. C.; Cho, K. Incorporation and Release Behavior of Hydrophobic Drug in
Functionalized Poly(D, L-lactide)-Block-Poly(ethylene oxide) Micelles.
J. Contr. Release
2004,
94,
323-335.
77. La, S. B.; Okano, T.; Kataoka, K. Preparation and Characterization of Micelle-Forming Poly-
meric Drug Indomethacin-Incorporated Poly(ethylene oxide)-Poly(β-benzyl L-aspartate)
Block Copolymer Micelles.
J. Pharm. Sci.
1996,
85,
85-90.
78. Torchilin, V. P. Targeted Pharmaceutical Nanocarriers for Cancer Therapy and Imaging.
AAPS
J.
2007,
9,
E128-E147.
79. Pastorino, F.; Brignole, C.; Marimpietri, D.; Sapra, P.; Moase, E. H.; Allen, T. M.; Ponzoni,
M. Doxorubicin-Loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selec-
tively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice.
Cancer
Res.
2003,
63,
86-92.
80. Allen, T. M.; Mumbengegwi, D. R.; Charrois, G. J. Anti-CD19-Targeted Liposomal Doxorubi-
cin Improves the Therapeutic Efficacy in Murine B-cell Lymphoma and Ameliorates the Toxic-
ity of Liposomes with Varying Drug Release Rates.
Clin. Cancer Res.
2005,
11,
3567-3573.
81. Medina, O. P.; Pillarsettya, N.; Glekasa, A.; Punzalan, B.; Longo, V.; Gönen, M.; Zanzonico,
P.; Smith-Jones, P.; Larson, S. M. Optimizing Tumor Targeting of the Lipophilic EGFR-Bind-
ing Radiotracer SKI 243 Using a Liposomal Nanoparticle Delivery System.
J. Contr. Release
2011,
149,
292-298.
82. Emerich, D. F.; Thanos, C. G. The Pinpoint Promise of Nanoparticle-Based Drug Delivery and
Molecular Diagnosis.
Biomol. Eng.
2006,
23,
171-184.
